Developing new treatment avenues

Lead researcher - Professor Anne Willis, MRC Toxicology Unit, Cambridge and Dr Martin Turner, University of Cambridge
Understanding the role of eIF4B in the pathogenesis of Diffuse Large B-Cell Lymphoma
Amount awarded: £170,616
Award start date: 01 May 2015
Recruitment start date: 14 Jul 2017
Award duration: 3 years

We have shown that in diffuse large B-cell lymphoma (DLBCL) there is an increase in the levels of a protein called eIF4B.  Importantly, this increase is associated with poor prognosis of patients with DLBCL.  Our recent results suggest that this is due to eIF4B’s ability to specifically increase the synthesis of proteins that are required both for the survival of the tumour cell within the body and to overcome the effects of chemotherapeutic drugs.  In this project we propose to find new ways in which to inhibit the function of eIF4B. In the longer term, in collaboration with our partner laboratory in Cambridge we aim to provide new treatment options for individuals with DLBCL that do not respond to current treatments.